Background. Safety and immunogenicity of a new formulation of 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A , 22F*, 23F, 33F*) was evaluated in adults ≥65 years of age previously vaccinated with PPV23.
Methods. Study subjects who received PPV23 at least 1 year prior to study entry received a single dose of either PCV-15 or PCV-13 (125/arm) and were followed for safety for 14 days postvaccination. Serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured immediately prior and 30 days postvaccination. NCT02573081
Results. Safety profiles were comparable between PCV-15 and PCV-13 recipients. Following vaccination, serotype-specific antibody responses for the 13 shared serotypes were generally comparable between recipients of PCV-15 and PCV-13 for IgG GMCs and geometric mean fold rises (GMFRs), OPA GMTs and GMFRs, and percentages of subjects with ≥4-fold-rise from baseline. Recipients of PCV-15 had numerically higher IgG GMCs and OPA GMTs than PCV-13 recipients for two serotypes unique to PCV-15 (22F, 33F).
Conclusion. PCV-15 was generally well tolerated when given as a single dose to adults ≥65 years of age previously vaccinated with PPV23. Following vaccination, serotype-specific IgG GMCs and OPA GMTs were comparable between recipients of PCV-15 and PCV-13 for 13 shared serotypes.
* Background. The effectiveness of the quadrivalent live attenuated influenza vaccine (LAIV4) and inactivated influenza vaccines (IIV) has been evaluated in recent seasons using a number of different study designs (e.g., randomized controlled studies [RCT] , cohort studies and test-negative case-control [TNCC] studies). Effectiveness estimates from these studies have, in general, had very broad confidence intervals reflecting the small numbers of cases reported. We conducted a meta-analysis to more precisely estimate the effectiveness of both vaccine types for the 2016-2017 season.
Methods. LAIV4 and IIV efficacy and effectiveness studies conducted over the 2016-2017 influenza season were identified from the published literature and through personal communication with the study investigators. Effectiveness estimates from all available study designs were included in the meta-analysis to maximize use of all available data and because all studies included methods to minimize bias. The analysis provided average estimates of the LAIV4 and IIV efficacy across countries. A sensitivity analysis limited to TNCC studies was also conducted. Only effectiveness results for A/H3N2 strains were combined as circulation of other strains was minimal. The meta-analyses used a random effects model. Heterogeneity testing was performed.
Results. Seven studies conducted in children in the United States, Japan, Finland, Germany, thr UK, and Canada were identified including four TNCC studies, one cohort study and one RCT (Figure 1 ). Individual effectiveness estimates ranged from 29% to 74% for LAIV4 and from 31% to 56% for IIV. Heterogeneity testing for H3N2 strains was not statistically significant. The consolidated effectiveness estimate across studies for LAIV4 was 44% (95% CI: 24, 58) and for IIV was 45% (95% CI: 29, 58). Estimates for the sensitivity analysis limited to TNCC studies were 61% (95% CI: 40, 74) and 43% (95% CI: 32, 52) for LAIV4 and IIV, respectively.
Conclusion. Despite variability in estimates across studies, both LAIV4 and IIV showed moderate and comparable effectiveness in children for circulating H3N2 strains during the 2016-2017 influenza season. Background. Ceftriaxone-sulbactam-disodium EDTA (CSE) is being developed for Gram-negative infections caused by multidrug-resistant (MDR) bacteria. PLEA was a Phase 3, double-blind, multicenter, randomized study of CSE vs. meropenem (MR) for treatment of adults with complicated urinary tract infections (cUTI) or acute pyelonephritis (AP). Non-inferiority of CSE over MR at the EMA/FDA primary endpoints has been reported. The effect of baseline MIC on clinical and microbiological outcome at the test of cure (TOC) visit was investigated.
Disclosures
Methods. Adult patients were randomized 1:1 to receive either CSE (1 g ceftriaxone/500 mg Sulbactam/37 mg EDTA) every 12 h or MR 1g every 8 hours as 30 minutes IV infusion for 5-14 days. Oral step-down therapy was not allowed. Prior to dosing, urine specimens were collected, and MICs were conducted using CLSI methods for both study drugs. Patients that were nonsusceptible to MR were not included in the mMITT population.
Results. Of 230 subjects randomized, 143 (62.2%) were included in the mMITT population. Baseline Enterobacteriaceae was found in 131 (91.6%) patients, 67/74 (90.5%) in CSE and 64/69 (92.8%) in MR arm. Mean duration of IV therapy was 7 days. Favorable clinical and microbiological outcomes were observed in ≥90% patients for all MICs across the two study groups, with the exception of MIC 1 μg/mL in MR (associated with >20% failures). Overall, both clinical cure and microbiological eradication rates were higher in CSE as compared with MR (95.9% Vs. 89.9% and 94.6% vs. 88.4% respectively) ( Table 1) . Background. Eravacycline is a novel, fully synthetic fluorocycline antibiotic that was evaluated in three comparator-controlled studies for the treatment of complicated intra-abdominal infections (cIAI). The objective of this analysis was to evaluate the safety profile of eravacycline 1 mg/kg IV q12h for the treatment of cIAI.
Methods. Pooled data from one phase 2 and two phase 3 (IGNITE1 and IGNITE4) clinical trials in cIAI were analyzed. Patients in the trials were randomized to receive eravacycline 1 mg/kg IV q12h, ertapenem 1 g IV q24h, or meropenem 1 g IV q8h for 4-14 days. Overall treatment-emergent adverse events (TEAEs), serious TEAEs, and laboratory assessments were evaluated.
Results. Five hundred seventy-six patients were treated with eravacycline 1 mg/kg IV q12h and 547 patients with comparators (ertapenem and meropenem). Demographic and baseline characteristics were similar among the groups. Overall summary and common TEAEs are presented in Table 1 . None of the serious TEAEs or those leading to death were related to the study drug. Clinically notable laboratory abnormalities were relatively uncommon and occurred at similar frequencies in eravacycline-and comparator-treated patients. Comparators include ertapenem 1 g IV q24h and meropenem 1 g IV q8h.
